{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:43:56Z","timestamp":1780368236897,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["315"],"award-info":[{"award-number":["315"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["315"],"award-info":[{"award-number":["315"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["315"],"award-info":[{"award-number":["315"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41375-024-02485-3","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:15:02Z","timestamp":1733310902000},"page":"371-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0741-7776","authenticated-orcid":false,"given":"Saioa","family":"Arza-Apalategi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branco M. H.","family":"Heuts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia M.","family":"Bergevoet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"Meering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1465-3400","authenticated-orcid":false,"given":"Daan","family":"Gilissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal W. T. C.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Krippner-Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8857-9461","authenticated-orcid":false,"given":"Peter J. M.","family":"Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-6483","authenticated-orcid":false,"given":"Olaf","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-568X","authenticated-orcid":false,"given":"Joop H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost H. A.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-8643","authenticated-orcid":false,"given":"Bert A.","family":"van der Reijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"2485_CR1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2485_CR2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2485_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103\u201312.","journal-title":"Nat Med"},{"key":"2485_CR4","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.leu.2401014","volume":"12","author":"GJ Swansbury","year":"1998","unstructured":"Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM. Hematological malignancies with t(9;11)(p21\u201322;q23) \u2013 a laboratory and clinical study of 125 cases. Leukemia. 1998;12:792\u2013800.","journal-title":"Leukemia"},{"key":"2485_CR5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev-pathol-011811-132434","volume":"7","author":"AG Muntean","year":"2012","unstructured":"Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 2012;7:283\u2013301.","journal-title":"Annu Rev Pathol"},{"key":"2485_CR6","doi-asserted-by":"crossref","first-page":"240371","DOI":"10.3389\/fped.2017.00004","volume":"5","author":"AC Winters","year":"2017","unstructured":"Winters AC, Bernt KM. MLL-rearranged leukemias- An update on science and clinical approaches. Front Pediatr. 2017;5:240371\u2013240371.","journal-title":"Front Pediatr."},{"key":"2485_CR7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818\u201322.","journal-title":"Nature"},{"key":"2485_CR8","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/onc.2016.488","volume":"36","author":"KHM Prange","year":"2017","unstructured":"Prange KHM, Mandoli A, Kuznetsova T, Wang SY, Sotoca AM, Marneth AE, et al. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Oncogene. 2017;36:3346\u201356.","journal-title":"Oncogene"},{"key":"2485_CR9","doi-asserted-by":"crossref","unstructured":"Chen X, Burkhardt DB, Hartman AA, Hu X, Eastman AE, Sun C, et al. MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors. Nat Commun. 2019;10:5767.","DOI":"10.1038\/s41467-019-13666-5"},{"key":"2485_CR10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.molcel.2022.02.013","volume":"82","author":"SN Olsen","year":"2022","unstructured":"Olsen SN, Godfrey L, Healy JP, Choi YA, Kai Y, Hatton C, et al. MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. Mol Cell. 2022;82:1140\u201355.e1111.","journal-title":"Mol Cell"},{"key":"2485_CR11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2485_CR12","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.3324\/haematol.2014.107128","volume":"99","author":"H Matsuo","year":"2014","unstructured":"Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, et al. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia. Haematologica. 2014;99:e225\u2013227.","journal-title":"Haematologica"},{"key":"2485_CR13","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","volume":"28","author":"S Lugthart","year":"2010","unstructured":"Lugthart S, Gr\u00f6schel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28:3890\u20138.","journal-title":"J Clin Oncol"},{"key":"2485_CR14","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/blood-2012-02-405019","volume":"119","author":"SM Noordermeer","year":"2012","unstructured":"Noordermeer SM, Monteferrario D, Sanders MA, Bullinger L, Jansen JH, van der Reijden BA. Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression. Blood. 2012;119:4335\u20137.","journal-title":"Blood"},{"key":"2485_CR15","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/leu.2010.211","volume":"24","author":"BV Balgobind","year":"2010","unstructured":"Balgobind BV, Zwaan CM, Reinhardt D, Arentsen-Peters TJCM, Hollink IHIM, de Haas V, et al. High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome. Leukemia. 2010;24:2048\u201355.","journal-title":"Leukemia"},{"key":"2485_CR16","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2011-11-393827","volume":"119","author":"EM Bindels","year":"2012","unstructured":"Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012;119:5838\u201349.","journal-title":"Blood"},{"key":"2485_CR17","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3324\/haematol.2019.225953","volume":"105","author":"Y Saito","year":"2020","unstructured":"Saito Y, Sawa D, Kinoshita M, Yamada A, Kamimura S, Suekane A, et al. EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase. Haematologica. 2020;105:2118\u201329.","journal-title":"Haematologica"},{"key":"2485_CR18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-021-00457-9","volume":"11","author":"C Birdwell","year":"2021","unstructured":"Birdwell C, Fiskus W, Kadia TM, Dinardo CD, Mill CP, Bhalla KN. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J. 2021;11:64\u201364.","journal-title":"Blood Cancer J"},{"key":"2485_CR19","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1182\/blood-2012-08-453662","volume":"122","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Owens K, Hatem L, Glass CH, Karuppaiah K, Camargo F, et al. Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia. Blood. 2013;122:2888.","journal-title":"Blood"},{"key":"2485_CR20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"2485_CR21","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","volume":"29","author":"C R\u00f6llig","year":"2011","unstructured":"R\u00f6llig C, Bornh\u00e4user M, Thiede C, Taube F, Kramer M, Mohr B, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29:2758\u201365.","journal-title":"J Clin Oncol"},{"key":"2485_CR22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12185-018-2488-1","volume":"109","author":"H Takei","year":"2019","unstructured":"Takei H, Kobayashi SS. Targeting transcription factors in acute myeloid leukemia. Int J Hematol. 2019;109:28\u201334.","journal-title":"Int J Hematol"},{"key":"2485_CR23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1535-7163.MCT-20-0115","volume":"20","author":"I Khan","year":"2021","unstructured":"Khan I, Eklund EE, Gartel AL. Therapeutic vulnerabilities of transcription factors in AML. Mol Cancer Ther. 2021;20:229\u201337.","journal-title":"Mol Cancer Ther"},{"key":"2485_CR24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.exphem.2014.04.012","volume":"42","author":"KHM Prange","year":"2014","unstructured":"Prange KHM, Singh AA, Martens JHA. The genome-wide molecular signature of transcription factors in leukemia. Exp Hematol. 2014;42:637\u201350.","journal-title":"Exp Hematol"},{"key":"2485_CR25","doi-asserted-by":"crossref","first-page":"7966","DOI":"10.1093\/nar\/gkab598","volume":"49","author":"Q Xu","year":"2021","unstructured":"Xu Q, Georgiou G, Frolich S, van der Sande M, Veenstra GJC, Zhou H, et al. ANANSE: an enhancer network-based computational approach for predicting key transcription factors in cell fate determination. Nucleic Acids Res. 2021;49:7966\u201385.","journal-title":"Nucleic Acids Res"},{"key":"2485_CR26","volume":"12","author":"BMH Heuts","year":"2022","unstructured":"Heuts BMH, Arza-Apalategi S, Fr\u00f6lich S, Bergevoet SM, van den Oever SN, van Heeringen SJ, et al. Identification of transcription factors dictating blood cell development using a bidirectional transcription network-based computational framework. Sci Rep. 2022;12:18656.","journal-title":"Sci Rep"},{"key":"2485_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. GigaScience. 2021;10:1\u20134.","journal-title":"GigaScience"},{"key":"2485_CR28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"},{"key":"2485_CR29","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.3324\/haematol.2014.110437","volume":"99","author":"FEM In\u2019t Hout","year":"2014","unstructured":"In\u2019t Hout FEM, van der Reijden BA, Monteferrario D, Jansen JH, Huls G. High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions. Haematologica. 2014;99:e257.","journal-title":"Haematologica"},{"key":"2485_CR30","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/bloodadvances.2020002953","volume":"4","author":"EH Bresnick","year":"2020","unstructured":"Bresnick EH, Jung MM, Katsumura KR. Human GATA2 mutations and hematologic disease: how many paths to pathogenesis? Blood Adv. 2020;4:4584.","journal-title":"Blood Adv"},{"key":"2485_CR31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.gene.2018.04.065","volume":"665","author":"X Wang","year":"2018","unstructured":"Wang X, Angelis N, Thein SL. MYB \u2013 A regulatory factor in hematopoiesis. Gene. 2018;665:6\u201317.","journal-title":"Gene"},{"key":"2485_CR32","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1158\/0008-5472.CAN-05-0147","volume":"65","author":"L Rainis","year":"2005","unstructured":"Rainis L, Toki T, Pimanda JE, Rosenthal E, Machol K, Strehl S, et al. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res. 2005;65:7596\u2013602.","journal-title":"Cancer Res"},{"key":"2485_CR33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/abbs\/gmab017","volume":"53","author":"Y Jia","year":"2021","unstructured":"Jia Y, Guo J, Zhao Y, Zhang Z, Shi L, Fang Y, et al. AHR signaling pathway reshapes the metabolism of AML\/MDS cells and potentially leads to cytarabine resistance. Acta Biochim Biophys Sin. 2021;53:492\u2013500.","journal-title":"Acta Biochim Biophys Sin"},{"key":"2485_CR34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1947601910377495","volume":"1","author":"M Dolores Delgado","year":"2010","unstructured":"Dolores Delgado M, Le\u00f3n J. Myc roles in hematopoiesis and leukemia. Genes Cancer. 2010;1:605.","journal-title":"Genes Cancer"},{"key":"2485_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040764","volume":"13","author":"F Liss","year":"2021","unstructured":"Liss F, Frech M, Wang Y, Giel G, Fischer S, Simon C, et al. IRF8 is an AML-specific susceptibility factor that regulates signaling pathways and proliferation of AML cells. Cancers. 2021;13:1\u201321.","journal-title":"Cancers"},{"key":"2485_CR36","doi-asserted-by":"crossref","first-page":"723137","DOI":"10.3389\/fonc.2021.723137","volume":"11","author":"D Xie","year":"2021","unstructured":"Xie D, Pei Q, Li J, Wan X, Ye T. Emerging role of E2F family in cancer stem cells. Front Oncol. 2021;11:723137.","journal-title":"Front Oncol"},{"key":"2485_CR37","doi-asserted-by":"crossref","first-page":"e0226212","DOI":"10.1371\/journal.pone.0226212","volume":"14","author":"S Nagel","year":"2019","unstructured":"Nagel S, Scherr M, MacLeod RAF, Pommerenke C, Koeppel M, Meyer C, et al. NKL homeobox gene activities in normal and malignant myeloid cells. PLoS ONE. 2019;14:e0226212.","journal-title":"PLoS ONE"},{"key":"2485_CR38","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.celrep.2018.12.098","volume":"26","author":"G Yi","year":"2019","unstructured":"Yi G, Wierenga ATJ, Petraglia F, Narang P, Janssen-Megens EM, Mandoli A, et al. Chromatin-based classification of genetically heterogeneous AMLs into two distinct subtypes with diverse stemness phenotypes. Cell Rep. 2019;26:1059\u201369.e1056.","journal-title":"Cell Rep"},{"key":"2485_CR39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3324\/haematol.2013.094243","volume":"98","author":"JH Martens","year":"2013","unstructured":"Martens JH, Stunnenberg HG. BLUEPRINT: mapping human blood cell epigenomes. Haematologica. 2013;98:1487\u20139.","journal-title":"Haematologica"},{"key":"2485_CR40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1101\/gad.949802","volume":"16","author":"B Ren","year":"2002","unstructured":"Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)\/M checkpoints. Genes Dev. 2002;16:245\u201356.","journal-title":"Genes Dev"},{"key":"2485_CR41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-021-01111-4","volume":"14","author":"SE Ahmadi","year":"2021","unstructured":"Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol. 2021;14:121.","journal-title":"J Hematol Oncol"},{"key":"2485_CR42","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.3390\/cancers15143624","volume":"15","author":"C Barone","year":"2023","unstructured":"Barone C, Orsenigo R, Cazzola A, D\u2019Errico E, Patelli A, Quattrini G, et al. Hematopoietic Stem Cell (HSC)-independent progenitors are susceptible to Mll-Af9-induced leukemic transformation. Cancers. 2023;15:3624.","journal-title":"Cancers"},{"key":"2485_CR43","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/leu.2012.363","volume":"27","author":"AV Krivtsov","year":"2013","unstructured":"Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk P, et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia. 2013;27:852\u201360.","journal-title":"Leukemia"},{"key":"2485_CR44","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/leu.2012.343","volume":"27","author":"SJ Horton","year":"2012","unstructured":"Horton SJ, Jaques J, Woolthuis C, van Dijk J, Mesuraca M, Huls G, et al. MLL\u2013AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia. 2012;27:1116\u201326.","journal-title":"Leukemia"},{"key":"2485_CR45","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1182\/bloodadvances.2020003490","volume":"6","author":"T Katsumoto","year":"2022","unstructured":"Katsumoto T, Ogawara Y, Yamagata K, Aikawa Y, Goitsuka R, Nakamura T, et al. MOZ is critical for the development of MOZ\/MLL fusion\u2013induced leukemia through regulation of Hoxa9\/Meis1 expression. Blood Adv. 2022;6:5527\u201337.","journal-title":"Blood Adv"},{"key":"2485_CR46","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1038\/onc.2010.254","volume":"29","author":"J Paggetti","year":"2010","unstructured":"Paggetti J, Largeot A, Aucagne R, Jacquel A, Lagrange B, Yang XJ, et al. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene. 2010;29:5019\u201331.","journal-title":"Oncogene"},{"key":"2485_CR47","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1128\/MCB.21.7.2249-2258.2001","volume":"21","author":"P Ernst","year":"2023","unstructured":"Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ. MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell Biol. 2023;21:2249\u201358.","journal-title":"Mol Cell Biol"},{"key":"2485_CR48","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/bloodadvances.2018016501","volume":"2","author":"M Germeshausen","year":"2018","unstructured":"Germeshausen M, Ancliff P, Estrada J, Metzler M, Ponstingl E, R\u00fctschle H, et al. MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia. Blood Adv. 2018;2:586\u201396.","journal-title":"Blood Adv"},{"key":"2485_CR49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dev.125.4.621","volume":"125","author":"W Wang","year":"1998","unstructured":"Wang W, Van De Water T, Lufkin T. Inner ear and maternal reproductive defects in mice lacking the Hmx3 homeobox gene. Development. 1998;125:621\u201334.","journal-title":"Development"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02485-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02485-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02485-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T10:55:04Z","timestamp":1738666504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02485-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2485"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02485-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients signed informed consent. The study was conducted in accordance with the Declaration of Helsinki and institutional guidelines and regulations from the Radboudumc Nijmegen (IRB number: CMO 2013\/064), reference number LHMH04.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}